We performed CRISPR CD19 gene knockout (KO) in two human B-cell tumor cell lines, Burkitt lymphoma (Raji) and ALL (Nalm6), to model disease relapse associated with CD19 loss. This evidence concerns the gene CD19 and Burkitt lymphoma.